SCHEMBL20656646

SCHEMBL20656646

CCCCC(CC)C(=O)NC(CO)CO

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.61
CA1 P00915 5/20 0.61
MAPK1 P28482 2/20 0.52
USP2 O75604 1/20 0.46
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 1/20 0.42
CA7 P43166 1/20 0.42
CA14 Q9ULX7 1/20 0.42
TSHR P16473 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PDF Q9HBH1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22304387 0.92 CA2 (0.50) CA2CA1MAPK1ALDH1A1PDF
SCHEMBL2058687 0.90 CA2 (0.68) CA2CA1MAPK1USP2ALDH1A1
SCHEMBL25732354 0.89 CA2 (0.66) CA2CA1MAPK1USP2ALDH1A1
SCHEMBL12873393 0.84 PDF (0.57) CA2CA1PDF
SCHEMBL11095965 0.81 CA2 (0.66) CA2CA1MAPK1USP2ALDH1A1
SCHEMBL9652484 0.81 CA2 (0.56) CA2CA1MAPK1USP2ALDH1A1
SCHEMBL21340001 0.80 HDAC8 (0.56) CA2CA1SMN1; SMN2LMNATSHR
SCHEMBL24124963 0.79 CA2 (0.53) CA2CA1MAPK1USP2PDF
SCHEMBL16389960 0.79 CA2 (0.63) CA2CA1MAPK1USP2ALDH1A1
SCHEMBL2058865 0.79 CA2 (0.63) CA2CA1MAPK1USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11607378-B2 Cosmetic composition comprising amide-based compound NEOPHARM CO., LTD. (KR) 2023-03-21 US disclosed
US-11446223-B2 Anti-aging composition NEOPHARM CO., LTD. (KR) 2022-09-20 US disclosed
CN-109843277-B Anti-inflammatory composition 株式会社新药 2022-08-02 CN disclosed
US-11285119-B2 Anti-inflammatory composition NEOPHARM CO., LTD. (KR) 2022-03-29 US disclosed
US-20210283031-A1 COSMETIC COMPOSITION COMPRISING AMIDE-BASED COMPOUND NEOPHARM CO., LTD. (KR) 2021-09-16 US disclosed
US-20210283031-A1 COSMETIC COMPOSITION COMPRISING AMIDE-BASED COMPOUND NEOPHARM CO., LTD. (KR) 2021-09-16 US disclosed
CN-109069454-B Anti-aging composition 株式会社新药 2021-09-07 CN disclosed
EP-3431082-B1 ANTI-AGING COMPOSITION NEOPHARM CO LTD (KR) 2021-06-09 EP disclosed
US-20200330352-A1 ANTI-AGING COMPOSITION NEOPHARM CO., LTD. (KR) 2020-10-22 US disclosed
US-20190262287-A1 ANTI-INFLAMMATORY COMPOSITION NEOPHARM CO., LTD. (KR) 2019-08-29 US disclosed
EP-3431082-A1 ANTI-AGING COMPOSITION Neopharm Co.,Ltd. (KR) 2019-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11446223-B2 Anti-aging composition COL14A1, CUTA, COL2A1 CA2 3119/4885CA1 4844/4885MAPK1 4040/4885
US-11607378-B2 Cosmetic composition comprising amide-based compound CUTA, TYR, ARG1 CA2 2908/4885CA1 4424/4885MAPK1 911/4885
US-20190262287-A1 ANTI-INFLAMMATORY COMPOSITION TNF, CUTA, IL6 CA2 4471/4885CA1 4655/4885MAPK1 2982/4885
US-11285119-B2 Anti-inflammatory composition TNF, CUTA, IL6 CA2 4471/4885CA1 4655/4885MAPK1 2982/4885
US-20210283031-A1 COSMETIC COMPOSITION COMPRISING AMIDE-BASED COMPOUND CUTA, TYR, ARG1 CA2 2908/4885CA1 4424/4885MAPK1 911/4885
US-20200330352-A1 ANTI-AGING COMPOSITION COL14A1, CUTA, COL2A1 CA2 3119/4885CA1 4844/4885MAPK1 4040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.